Business Wire

BioCell Technology Announces BioCell Collagen® Skin Aging Clinical Trial Poster Presentation at ASN Nutrition 2019

Del

BioCell Technology, LLC, a branded dietary ingredient supplier, today announced the presentation of The Effects of Skin Aging Associated with the Use of BioCell Collagen® in Healthy Adult Females: A Randomized, Double-blind, Placebo-controlled Clinical Trial. These results were presented in a poster session at the American Society for Nutrition (ASN) Nutrition 2019 on June 9, 2019, and are available at http://bit.ly/2WzhODi. This poster will be published as part of the proceedings of Nutrition 2019 by ASN. The manuscript of the study will be published in the online and print versions of the peer review journal Alternative Therapies in Health and Medicine (ATHM).

The goal of the study was to determine if a correlation existed between the effects of the dietary supplement, BioCell-Collagen®, with changes associated with skin aging. The study was a 128-female subject, 12-week, double-blind, placebo-controlled trial. Participants were randomly assigned to an intervention or a placebo. The intervention consisted of twice daily 500mg oral administration of BioCell Collagen®, a novel hydrolyzed chicken sternal cartilage extract dietary ingredient composed of a naturally-occurring matrix of collagen type-II peptides (≥300 mg), chondroitin sulfate (≥100 mg), and hyaluronic acid (≥50 mg).

For the 113 participants completing the study, BioCell Collagen® supplementation compared to a placebo resulted in:

  • Significantly reduced facial lines and wrinkles (P = .019) and crow’s feet lines and wrinkles (P = .05)
  • Increased skin elasticity (P = .008) and cutaneous collagen content (P < .001) by 12%
  • Improved indicators associated with a more youthful skin appearance based on visual grading and wrinkle width (P = .046)
  • Decreased skin dryness and erythema.
  • No difference existed between the supplement and the placebo for skin surface water content or retention. The supplement was well tolerated, with no reported adverse reactions.

“We are very excited to publish the findings of our largest study to date, which further supports the efficacy of our flagship dietary ingredient BioCell Collagen®. Human clinical studies continue to be the gold standard for substantiating dietary supplement claims and we take pride that our licensed partners can take advantage,” said Suhail Ishaq, president of BioCell Technology.

The latest study validates an earlier pilot study that demonstrated similar results- Schwartz SR, Park J. Ingestion of BioCell Collagen®, a novel hydrolyzed chicken sternal cartilage extract; enhanced blood microcirculation and reduced facial aging signs. Clin Interven Aging. 2012; 7: 267-273.

“An impressive example of how a series of studies, capped by a randomized, double-blind, placebo-controlled, supports a ‘beauty from within’ claim in healthy women. Even more impressive was that the results remained statistically significant even after an intention-to-treat analysis was performed that included the few subjects that dropped out of the study. Such an analysis is seen in only about 15-20% of randomized, placebo-controlled blinded clinical studies published in leading medical journals,” said Alexander Schauss, PhD, FACN, CFS, Senior Director of Research at AIBMR Life Sciences, and the corresponding author.

“It is important that the supplement industry conducts research at the pinnacle of good science and this includes a double blind, properly populated study like this one,” said Stephen Schwartz, President and CEO of International Research Services, Inc.

About BioCell Collagen ®

BioCell Collagen® is a clinically tested branded dietary ingredient that promotes active joints, youthful-looking skin, and healthy connective tissues. BioCell Collagen® contains a patented composition of naturally occurring hydrolyzed collagen type II peptides, chondroitin sulfate and hyaluronic acid in a highly absorbable matrix form that has been the subject of numerous human clinical trials, including trials on safety, efficacy, and bioavailability. BioCell Collagen® is self-affirmed GRAS (Generally Recognized As Safe). BioCell Collagen® is non-GMO and free of gluten, soy, shellfish, fish, egg, milk, peanuts and sugar. BioCell Collagen® is made exclusively in the USA and Europe. For more information, visit www.BioCellCollagen.com.

About BioCell Technology, LLC

BioCell Technology is a research, product development, branding, and marketing company that manufactures innovative, science-based ingredients that have applications in dietary supplements, functional foods and cosmetics. The company licenses its branded ingredients to leading consumer packaged goods companies for use in their finished products. For more information visit www.BioCellTechnology.com .

Contact information

Suhail Ishaq
President of BioCell Technology, LLC
714-632-1231

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Three Finalists Selected Following GA-ASI’s Blue Magic Belgium Event15.6.2019 11:00:00 CESTPressemelding

Three finalists have been selected from GA-ASI’s Blue Magic Belgium event with the goal of supporting GA-ASI and the development of MQ-9B SkyGuardian Remotely Piloted Aircraft (RPA) for Belgium. The three Belgian companies selected are AIRobot, ALX Systems, and Hexagon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190615005003/en/ "We were very impressed by the many talented companies and particularly by the innovative concepts presented by these three finalists," said Linden Blue, CEO, GA-ASI. (Photo: Business Wire) AIRobot, a company based at DronePort in Sint Truiden, Belgium, focuses on developing drone performance equipment for easy, precise and safe professional operations, while specializing in Artificial Intelligence (AI) for processing hyper-spectral imagery. ALX Systems is an Unmanned Aircraft System (UAS) solution provider based in Liège, Belgium and specializing in AI for processing Full Motion Video. Hexagon’s

World’s First E-Money License for Blockchains Issued to Monerium15.6.2019 08:35:00 CESTPressemelding

Monerium ehf. has received a license from the Financial Supervisory Authority of Iceland to issue e-money on blockchains through its subsidiary, Monerium EMI ehf. The full license is the world’s first e-money license for blockchains issued under EU e-money regulations. The license is passportable within the largest global economic zone, the European Economic Area, and to external jurisdictions subject to regulatory approval and destination country regulations. Designed as a digital alternative to cash, e-money is a proven framework for digital fiat currency already in use for pre-paid cards and mobile wallets. By issuing e-money on blockchains, Monerium removes the need for intermediaries and provides the ability to automate financial transactions in many sectors, including payments, trade finance, securities settlement, and ecommerce. At the same time, e-money on blockchains extends Satoshi Nakamoto’s vision of online peer-to-peer currency transactions to a regulated form of digital f

Mattel® Unveils Hot Wheels™ id, Groundbreaking New Play System Bringing Together Physical and Digital Play, Available Exclusively at Apple.com, Select Apple Stores and on the App Store14.6.2019 13:00:00 CESTPressemelding

Mattel, Inc. (NASDAQ: MAT) today announced the launch of Hot Wheels id, the evolution of the beloved brand that generations of kids have played with to ignite their challenger spirit. Through innovative vehicle play, Hot Wheels id brings together physical and digital in a Mixed Play experience with uniquely identifiable vehicles, a smart Race Portal, Smart Track, and digital hub, so you can build your personalized fleet, measure your performance, and compete like never before. Hot Wheels id is available starting June 14th exclusively at Apple.com, select Apple stores and on the App Store. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190614005084/en/ Hot Wheels Race Portal™ scans your Hot Wheels id vehicles into the app, tracks speed and counts laps via infrared sensors, and easily connects with your classic Hot Wheels track. (Photo: Business Wire) For the first time in history, kids can scan their Hot Wheels id cars digita

S BLOCK Co-host With World Blockchain Forum Singapore & World Blockchain Award Asia14.6.2019 12:45:00 CESTPressemelding

Asia's highly anticipated blockchain event World Blockchain Forum · Singapore & World Blockchain Award · Asia will be held on June 22-23, 2019 at the Marina Bay Sands in Singapore. The conference will bring together more than 4,000 global elites from government, associations, regulatory agencies, investment institutions, blockchain project parties, financial technology, and media to discuss industry trends and innovations, jointly recognizing industry pioneers and contributions to promote the industry and achieve healthy and rapid development! The World Blockchain Forum Singapore & World Blockchain Award Asia will be co-hosted by S BLOCK. As a fast-growing digital asset management platform, S BLOCK was developed for the blockchain industry. This rapidly growing platform aims to serve the digital financial ecosystem and aims to commercialize by the end of 2019. The slogan of S BLOCK is “unleash your digital asset.” The platform also provides investors access to mainstream cryptocurrenci

Janssen Reports Top-Line Phase 3 Results for TREMFYA® (guselkumab) in Adults with Active Psoriatic Arthritis14.6.2019 11:39:00 CESTPressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced top-line results from the Phase 3 DISCOVER 1 and 2 studies, which evaluated the efficacy and safety of guselkumab compared to placebo in adult patients with active moderate to severe psoriatic arthritis (PsA). Both studies met their primary endpoints of American College of Rheumatology 20% improvement (ACR20), and the safety profiles observed for guselkumab in the DISCOVER programme were consistent with previous studies of guselkumab and current prescribing information.1 The DISCOVER programme comprises the first-ever Phase 3 studies evaluating an IL-23 p19 inhibitor for the treatment of psoriatic arthritis, and data will be presented at upcoming scientific medical meetings. Data from the two DISCOVER studies will serve as the basis of submissions to the U.S. Food and Drug Administration and European Medicines Agency seeking approval of guselkumab as a treatment for psoriatic arthritis, which are anticipated for

Velodyne Features Advanced Lidar for Port Terminal Automation at TOC Europe14.6.2019 10:00:00 CESTPressemelding

Velodyne Lidar, Inc. (Stand A50) will demonstrate how its smart, powerful lidar solutions can advance port terminal automation at TOC Europe in Rotterdam, 18-20 June. Velodyne will highlight customer applications that show how its lidar sensors can be used in crane steering, container handling, internal terminal vehicles (ITV), automated guided vehicles (AGV), forklifts, and terminal security/yard monitoring systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190614005040/en/ DGWorld solutions demonstrate how Velodyne’s intelligent lidar sensors are helping port and terminal operators deliver consistent service quality and achieve increased safety. (Photo: Business Wire) DGWorld (Stand B21A), a Dubai-based Velodyne integrator, will showcase autonomous taxis, ITVs, AGVs, and terminal operation vehicles that use Velodyne lidar sensors to run autonomously. These vehicles use advanced artificial intelligence (AI), automation